Skip to main content
Clinical Trials/CTRI/2015/01/005455
CTRI/2015/01/005455
Recruiting
Phase 2

Clinical evaluation of Kushmandak Rasayana in the management of Chronic Bronchitis (Kaphaja kasa) - CKMCB

Central Council for Research in Ayurvedic Sciences CCRAS0 sites195 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Central Council for Research in Ayurvedic Sciences CCRAS
Enrollment
195
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Central Council for Research in Ayurvedic Sciences CCRAS

Eligibility Criteria

Inclusion Criteria

  • 1 Patients of either sex aged between 18 to 70 years.
  • 2 Patients with documented history of stable Chronic Bronchitis having persistent cough that produces sputum and mucus most of the days, for \>\= three months per year for \>\= 2 consecutive years.
  • 3 Patients having FEV 1 between 50% \-80% of predicted value.
  • 4 Patient willing and able to participate in the study for 14 weeks.

Exclusion Criteria

  • 1 Presence of other pulmonary diseases or allergies like Emphysema, Cor pulmonale, Cyanosis, Pneumonia, Bronchial Asthma, Cystic fibrosis, Tuberculosis, Lung cancer, Pulmonary eosinophilia etc.
  • 2 Patients having pulmonary infections other than Chronic Bronchitis.
  • 3 Diabetes Mellitus
  • 4 Patients on prolonged (over 6 weeks) medication with corticosteroids, bronchodilators, Mast cell stabilizers, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
  • 5 Patients suffering from major systemic illness necessitating long term drug treatment
  • (Rheumatoid arthritis, Tuberculosis, Psycho Neuro Endocrinal disorders, etc.)
  • 6 Patients with past history of unstable cardiovascular diseases.
  • 7 Patients with concurrent serious hepatic disorder defined as Aspartate AminoTransferase (AST) and or Alanine Amino Transferase (ALT), defined as over 2 times upper normal limit or Renal Disorders (defined as Serum Creatinine more then 1\.2 mgdL).
  • 8 Alcoholics and or drug abusers.
  • 9\.History of hypersensitivity to the trial drug or any of its ingredients.

Outcomes

Primary Outcomes

Not specified

Similar Trials